Jasper Therapeutics (JSPR) Competitors $7.04 +0.22 (+3.17%) Closing price 03:54 PM EasternExtended Trading$6.90 -0.13 (-1.86%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JSPR vs. AARD, OLMA, AVTE, OCGN, GLUE, AVIR, PRME, TKNO, RCKT, and LFCRShould you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Aardvark Therapeutics (AARD), Olema Pharmaceuticals (OLMA), Aerovate Therapeutics (AVTE), Ocugen (OCGN), Monte Rosa Therapeutics (GLUE), Atea Pharmaceuticals (AVIR), Prime Medicine (PRME), Alpha Teknova (TKNO), Rocket Pharmaceuticals (RCKT), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry. Jasper Therapeutics vs. Its Competitors Aardvark Therapeutics Olema Pharmaceuticals Aerovate Therapeutics Ocugen Monte Rosa Therapeutics Atea Pharmaceuticals Prime Medicine Alpha Teknova Rocket Pharmaceuticals Lifecore Biomedical Aardvark Therapeutics (NASDAQ:AARD) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends. Which has higher valuation & earnings, AARD or JSPR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAardvark TherapeuticsN/AN/A-$20.59MN/AN/AJasper TherapeuticsN/AN/A-$71.27M-$5.24-1.34 Do institutionals and insiders have more ownership in AARD or JSPR? 79.9% of Jasper Therapeutics shares are owned by institutional investors. 4.6% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer AARD or JSPR? In the previous week, Aardvark Therapeutics had 10 more articles in the media than Jasper Therapeutics. MarketBeat recorded 11 mentions for Aardvark Therapeutics and 1 mentions for Jasper Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.67 beat Jasper Therapeutics' score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is AARD or JSPR more profitable? Aardvark Therapeutics' return on equity of 0.00% beat Jasper Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aardvark TherapeuticsN/A N/A N/A Jasper Therapeutics N/A -109.45%-89.82% Do analysts recommend AARD or JSPR? Aardvark Therapeutics presently has a consensus price target of $33.00, indicating a potential upside of 137.07%. Jasper Therapeutics has a consensus price target of $59.25, indicating a potential upside of 742.10%. Given Jasper Therapeutics' higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than Aardvark Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Jasper Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAardvark Therapeutics beats Jasper Therapeutics on 5 of the 9 factors compared between the two stocks. Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JSPR vs. The Competition Export to ExcelMetricJasper TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.45M$2.91B$5.54B$8.96BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-1.347.3219.2119.61Price / SalesN/A281.53421.06119.62Price / CashN/A41.9536.6357.47Price / Book1.717.518.085.67Net Income-$71.27M-$55.05M$3.16B$248.47M7 Day Performance23.66%3.16%2.12%2.90%1 Month Performance19.25%5.92%4.43%5.75%1 Year Performance-68.32%5.82%35.62%21.36% Jasper Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JSPRJasper Therapeutics1.8953 of 5 stars$7.04+3.2%$59.25+742.1%-70.1%$102.45MN/A-1.3420Positive NewsAARDAardvark TherapeuticsN/A$13.33+19.8%$31.25+134.4%N/A$289.26MN/A0.0018News CoverageAnalyst ForecastAnalyst RevisionGap UpOLMAOlema Pharmaceuticals2.5162 of 5 stars$4.19+1.5%$24.50+484.7%-56.4%$286.68MN/A-2.0870News CoverageAVTEAerovate TherapeuticsN/A$9.89+5.1%N/A-82.4%$286.66MN/A-3.3120High Trading VolumeOCGNOcugen1.0264 of 5 stars$0.98-7.4%$6.00+511.6%-42.5%$286.51M$4.52M-5.1680High Trading VolumeGLUEMonte Rosa Therapeutics1.1961 of 5 stars$4.64+0.2%$15.50+234.1%+31.8%$285.41M$75.62M58.0190News CoverageAVIRAtea Pharmaceuticals2.3927 of 5 stars$3.32+2.2%$6.00+80.7%+12.4%$284.13MN/A-2.0170News CoveragePRMEPrime Medicine3.5849 of 5 stars$2.16+4.3%$10.08+366.8%-41.9%$283.60M$3.85M-1.05234Gap UpHigh Trading VolumeTKNOAlpha Teknova3.0464 of 5 stars$5.28-5.0%$8.50+61.0%+313.8%$282.16M$37.74M-11.00240News CoverageRCKTRocket Pharmaceuticals4.8856 of 5 stars$2.63-2.6%$18.60+607.2%-85.4%$280.86MN/A-1.00240Trending NewsLFCRLifecore Biomedical1.6267 of 5 stars$7.39+6.5%$8.00+8.3%+70.3%$273.65M$128.26M-5.10690Positive News Related Companies and Tools Related Companies Aardvark Therapeutics Alternatives Olema Pharmaceuticals Alternatives Aerovate Therapeutics Alternatives Ocugen Alternatives Monte Rosa Therapeutics Alternatives Atea Pharmaceuticals Alternatives Prime Medicine Alternatives Alpha Teknova Alternatives Rocket Pharmaceuticals Alternatives Lifecore Biomedical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JSPR) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JSPR Stock Alerts